雷珠单抗生物类似药SB11与参照雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效与安全性随机临床试验
这项在9国75中心开展的随机双盲3期等效性研究纳入705例50岁以上新生血管性AMD患者,比较SB11与参照雷珠单抗每4周玻璃体腔注射0.5 mg至48周的疗效与安全性。第8周BCVA变化组间调整差异为-0.8字母(90%CI -1.8至0.2),第4周CST变化调整差异为-8 μm(95%CI -19至3 μm),均落在预设等效界值内,安全性与免疫原性相似。
要点
- 第8周BCVA变化SB11组6.2字母 vs 参照组7.0字母,调整差异-0.8字母(90%CI -1.8至0.2),符合等效。
- 第4周CST变化SB11组-108 μm vs 参照组-100 μm,调整差异-8 μm(95%CI -19至3 μm),符合等效。
- 治疗中出现的不良事件、严重不良事件及抗药抗体累积发生率两组相似。
核心结论
- SB11与参照雷珠单抗在新生血管性AMD患者中显示出等效疗效、相似安全性和相似免疫原性,支持SB11用于该类患者。
研究设计与样本
- 随机、双盲、平行组3期等效性研究,2018年3月14日至2019年12月9日在9国75个中心开展。
- 纳入705例50岁及以上新生血管性AMD伴活动性黄斑下脉络膜新生血管病变的参与者,按意向治疗分析。
- 干预为每4周玻璃体腔注射SB11或雷珠单抗0.5 mg,持续至第48周。
主要发现
- 第8周BCVA较基线最小二乘均值(SE)变化:SB11组6.2(0.5)字母,参照组7.0(0.5)字母,调整治疗差异-0.8字母(90%CI -1.8至0.2)。
- 第4周CST较基线最小二乘均值(SE)变化:SB11组-108(5)μm,参照组-100(5)μm,调整治疗差异-8 μm(95%CI -19至3 μm)。
- 治疗中出现的不良事件:SB11组231/350(66.0%),参照组237/354(66.9%);严重不良事件分别为44/350(12.6%)与44/354(12.4%)。
- 导致停药的治疗中出现不良事件:SB11组8/350(2.3%),参照组5/354(1.4%)。
- 截至第24周抗药抗体累积发生率:SB11组3.0%(10/330),参照组3.1%(10/327)。
关键数值与推荐
- 主要疗效终点预设等效界值:BCVA调整治疗差异-3至3字母,CST调整治疗差异-36至36 μm。
- 第8周BCVA调整差异-0.8字母(90%CI -1.8至0.2)落在等效界值内。
- 第4周CST调整差异-8 μm(95%CI -19至3 μm)落在等效界值内。
临床怎么用
- SB11可作为参照雷珠单抗的等效替代用于新生血管性AMD的玻璃体腔注射治疗。
- 治疗中需关注不良事件及抗药抗体,但本研究显示两组发生率相似且免疫原性低。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment. OBJECTIVE: To demonstrate equivalence of efficacy, similar safety, and similar immunogenicity of SB11 compared with the reference ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-masked, parallel-group phase 3 equivalence study was conducted in 75 centers in 9 countries from March 14, 2018, to December 9, 2019, among 705 participants 50 years or older with neovascular age-related macular degeneration with active subfoveal choroidal neovascularization lesions. Analysis was performed on an intent-to-treat basis. INTERVENTIONS: Intravitreous injection of SB11 or ranibizumab, 0.5 mg, every 4 weeks through week 48. MAIN OUTCOMES AND MEASURES: Preplanned interim analysis after all participants completed the week 24 assessment of primary efficacy end points at week 8 for change from baseline in best-corrected visual acuity (BCVA) and week 4 for central subfield thickness (CST), with predefined equivalence margins for adjusted treatment differences of -3 letters to 3 letters for BCVA and -36 μm to 36 μm for CST. RESULTS: Baseline and disease characteristics among 705 randomized participants (403 women [57.2%]; mean [SD] age, 74.1 [8.5] years) were comparable between treatment groups (SB11, 351; ranibizumab, 354). Least-squares mean (SE) changes in BCVA from baseline at week 8 were 6.2 (0.5) letters in the SB11 group vs 7.0 (0.5) letters in the ranibizumab group, with an adjusted treatment difference of -0.8 letter (90% CI, -1.8 to 0.2 letters). Least-squares mean (SE) changes in CST from baseline at week 4 were -108 (5) μm in the SB11 group vs -100 (5) μm in the ranibizumab group, with an adjusted treatment difference of -8 μm (95% CI, -19 to 3 μm). Incidences of treatment-emergent adverse events (231 of 350 [66.0%] vs 237 of 354 [66.9%]), including serious treatment-emergent adverse events (44 of 350 [12.6%] vs 44 of 354 [12.4%]) and treatment-emergent adverse events leading to study drug discontinuation (8 of 350 [2.3%] vs 5 of 354 [1.4%]), were similar in the SB11 and ranibizumab groups. Immunogenicity was low, with a cumulative incidence of antidrug antibodies up to week 24 of 3.0% (10 of 330) in the SB11 group and 3.1% (10 of 327) in the ranibizumab group. CONCLUSIONS AND RELEVANCE: These findings of equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab support the use of SB11 for patients with neovascular age-related macular degeneration. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03150589.
引用
- Woo SJ, Veith M, Hamouz J, et al. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 33211076. doi:10.1001/jamaophthalmol.2020.5053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。